Medicine and Dentistry
Abdominal Aortic Aneurysm
35%
Acute Myelogenous Leukemia
35%
Acute Myeloid Leukemia
77%
Adult Hematology
35%
Allogeneic Stem Cell Transplantation
69%
Allotransplantation
35%
Aneurysm
20%
Aneurysm Surgery
35%
Aortic Aneurysm
35%
Autophagy
17%
Cancer
35%
Cell Transplantation
82%
Cohort Analysis
35%
Cyclophosphamide
35%
Decitabine
35%
Disseminated Herpes Zoster
35%
Erythroblast
17%
Erythroid Cell
35%
Funnel Plot
17%
Graft Versus Host Reaction
34%
Hemagglutinin
11%
Hematology
11%
Hematopoietic Stem Cell
100%
Hematopoietic Stem Cell
35%
Human Parainfluenza Virus 3
35%
Hyperglycemia
35%
Hypomethylating Agent
35%
Immune Deficiency
35%
Immunogenicity
35%
Immunosuppressive Treatment
44%
Infection Control
35%
Logistic Regression Analysis
11%
Microenvironment
35%
Minimal Residual Disease
35%
Molecular Epidemiology
35%
Mononuclear Cell
17%
Mortality Rate
47%
Myelodysplastic Syndrome
35%
Myelofibrosis
35%
Myeloid Malignancy
35%
Overall Survival
76%
Postoperative Complication
11%
Precursor
17%
Programmed Cell Death
35%
Prospective Study
35%
Recurrence Free Survival
20%
Solid Malignant Neoplasm
17%
Stem Cell Therapy
35%
Survival Rate
25%
Transplantation
27%
Keyphrases
Abdominal Aortic Aneurysm Surgery
35%
Acute Myeloid Leukemia
35%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
26%
Allogeneic Hemopoietic Stem Cell Transplantation
35%
Apoptosis
17%
Autophagy
17%
Bovine Parainfluenza Virus Type 3 (BPIV3)
35%
Cellular Context
17%
Complex EVAR
35%
Continuous Glucose Monitoring
35%
Conventional Chemotherapy
35%
Decitabine
35%
Erythroblasts
17%
Erythroid Cells
35%
Erythroid Progenitors
35%
Failure to Rescue
35%
Glucose Level
10%
Graft-versus-host Disease (GvHD)
35%
Hemagglutinin-neuraminidase Gene
11%
Hematopoietic Cells
17%
Hospital Compare
35%
Hospital Volume
10%
Hyperglycemia
20%
Immune Treatment
11%
Intensive Chemotherapy
15%
Low-risk Myelodysplastic Syndromes
35%
Major Complications
16%
Microenvironment
35%
Minimal Residual Disease
35%
Mobilization Failure
35%
Mononuclear Cell Fraction
17%
Mortality Rate
35%
Myelodysplastic
17%
Netherlands
35%
Older AML
35%
Older Patients
35%
Oral mucosa
35%
Oral Participation
35%
Poor Mobilization
17%
Poor Mobilizers
23%
Precursor Cells
17%
Pretransplant
35%
Programmed Cell Death
17%
Quality Assessment
35%
Reduced Immunogenicity
11%
Ruxolitinib
35%
Secondary Immunodeficiency
35%
Severe Hyperglycemia
35%
Steroid-refractory
35%
Team Quality
35%
Immunology and Microbiology
Allogeneic Stem Cell Transplantation
23%
Allotransplantation
35%
B Cell
11%
CD34
5%
Cell Transplantation
73%
Chronic Graft Versus Host Disease
47%
Comorbidity
5%
Conditioning
5%
Cyclophosphamide
35%
Gene Frequency
11%
Graft-Versus-Host Disease
64%
Hemagglutinin-Neuraminidase
11%
Hematopoiesis
35%
Hematopoietic Cell
85%
Herpes Zoster
23%
Human Immunodeficiency Virus
11%
Human Parainfluenza Virus 3
35%
Immunodeficiency
35%
Immunogenicity
35%
Immunosuppressive Drug
23%
Molecular Epidemiology
35%
Mouth
35%
Mouth Mucosa
70%
Myeloid
82%
Next Generation Sequencing
5%
Overall Survival
47%
Recurrence Free Survival
17%
Rituximab
11%
Stem Cell
35%
Subunit Vaccine
11%
Survival Rate
23%
Transplant Procedure
23%
Vaccination Schedule
11%
Varicella Zoster Virus
11%
